Clinical DevelopmentSION’s clinical development team has previously worked at Vertex, bringing valuable experience to their current efforts.
CompetitionSION's programs are seen as much-needed competition in the cystic fibrosis space.
Drug DevelopmentSionna Therapeutics is developing two NBD1 stabilizers, SION-451 & SION-719, which are likely superior to the standard of care Trikafta.